Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

By Sriparna Roy (Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant ...

(Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a ...

Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

Neurocrine Biosciences' valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

Find out how LB Pharmaceuticals’ LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute ...